The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vor Biopharma Inc. is $40.00, about 71.2% above its August 10 closing price of $23.37
Key quarterly figure
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$62.80 mln
$35.68 mln (9 Analysts)
Outlook and trial timeline
Vor Bio anticipates topline Phase 3 UPSTREAM MG trial results in 1H 2027
Company expects cash and investments to fund operations into early 2029
Enrollment is ongoing for Phase 3 UPSTREAM SjD trial in primary Sjögren’s disease
Quarterly loss and expense drivers
US biotech firm's Q2 net loss widened, missing analyst expectations
R&D expenses dropped sharply yr/yr due to prior licensing costs and workforce reductions
Company attributed higher Q2 G&A expenses to increased stock-based compensation, personnel, and commercial-related costs
VOR•
